Cargando…

Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma

BACKGROUND & AIMS: Infigratinib is a pan‐FGFR (fibroblast growth factor receptor) inhibitor that has shown encouraging activity in FGFR‐dependent hepatocellular carcinoma (HCC) models. However, long‐term treatment results in the emergence of resistant colonies. We sought to understand the mechan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prawira, Aldo, Le, Thi Bich Uyen, Vu, Thanh Chung, Huynh, Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Liver Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894323/ https://www.ncbi.nlm.nih.gov/pubmed/33179425 http://dx.doi.org/10.1111/liv.14728

Ejemplares similares

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor
por: Prawira, Aldo, et al.
Publicado: (2021)

Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma
por: Paur, Jakob, et al.
Publicado: (2020)

FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2020)

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
por: Lu, Hengyu, et al.
Publicado: (2020)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
por: Park, Joong-Won, et al.
Publicado: (2015)

Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2020)

A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection
por: Klompenhouwer, Anne J., et al.
Publicado: (2020)

Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course
por: van Rosmalen, Belle V., et al.
Publicado: (2021)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis
por: Costentin, Charlotte E., et al.
Publicado: (2022)

Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI
por: Jiang, Hanyu, et al.
Publicado: (2022)

Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma
por: Gao, Xu-dong, et al.
Publicado: (2014)

Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma
por: Huynh, Hung, et al.
Publicado: (2019)

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
por: Lassman, Andrew B., et al.
Publicado: (2022)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements
por: White, Kathryn, et al.
Publicado: (2023)

Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence
por: Giordano, Silvia, et al.
Publicado: (2020)

Nationwide treatment and outcomes of perihilar cholangiocarcinoma
por: van Keulen, Anne‐Marleen, et al.
Publicado: (2021)

Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory
por: Li, Chenxi, et al.
Publicado: (2022)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
por: Muñoz‐Martínez, Sergio, et al.
Publicado: (2022)

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01
por: Jarman, Edward J., et al.
Publicado: (2022)

Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
por: Shiina, Shuichiro, et al.
Publicado: (2012)

Correction to: Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

CT With Hepatic Arterioportography as a Pretreatment Examination for Hepatocellular Carcinoma Patients: A Randomized Controlled Trial
por: Ohki, Takamasa, et al.
Publicado: (2013)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

Alpha‐fetoprotein‐adjusted‐to‐HCC‐size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma
por: Meischl, Tobias, et al.
Publicado: (2021)

Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England
por: Reeves, Helen L, et al.
Publicado: (2022)

Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
por: Yeoh, Kheng Wei, et al.
Publicado: (2020)

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
por: Demuynck, Benoit, et al.
Publicado: (2020)

CXCR4 Expression Predicts Early Liver Recurrence and Poor Survival After Resection of Pancreatic Adenocarcinoma
por: Liao, Wei-Chih, et al.
Publicado: (2012)

Early hepatocellular carcinoma
por: Jin, So-Young, et al.
Publicado: (2011)

MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma
por: Grisetti, Luca, et al.
Publicado: (2022)

Percutaneous cryoablation for hepatocellular carcinoma
por: Song, Kyoung Doo
Publicado: (2016)

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b26apl0c59m8hl9i9kdod7rict